119 related articles for article (PubMed ID: 37596865)
1. Clinicopathological features, treatment modalities, and prognosis of esophageal neuroendocrine carcinoma: A single-center retrospective study.
Zhang Y; Liao JT; Lin Y; Liu C; Wu ZH; Yu B; Sun S; Yu H; Hui XH; Wu XH; Zhao XM; Wang HJ; Zheng Q; Li Y; Hu ZH; Wang JL
J Dig Dis; 2023; 24(8-9):472-479. PubMed ID: 37596865
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study.
Chen C; Hu H; Zheng Z; Yang Y; Chen W; Qiao X; Li P; Zhang S
Cancer Med; 2022 Dec; 11(24):4935-4945. PubMed ID: 35596661
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological analysis of 67 cases of esophageal neuroendocrine carcinoma and the effect of postoperative adjuvant therapy on prognosis.
Liu S; Ge X; Gao Z; Zhou Q; Shi Y; Jiang W; Yang M; Sun X
Medicine (Baltimore); 2021 Oct; 100(43):e27302. PubMed ID: 34713821
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.
Sohda M; Saeki H; Kuwano H; Miyazaki T; Yokobori T; Sano A; Sakai M; Kakeji Y; Toh Y; Doki Y; Matsubara H
Ann Surg Oncol; 2021 Nov; 28(12):7983-7989. PubMed ID: 33843025
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
6. The clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population.
Zhang X; Lv Z; Lou H
BMC Cancer; 2019 Jan; 19(1):22. PubMed ID: 30616631
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study.
Zhou Y; Hou P; Zha KJ; Wang F; Zhou K; He W; Gao JB
World J Gastroenterol; 2020 Aug; 26(31):4680-4693. PubMed ID: 32884225
[TBL] [Abstract][Full Text] [Related]
8. Incidence, treatment, and survival analysis in esophageal neuroendocrine carcinoma population.
Li Z; Hu J; Chen P; Zeng Z
Transl Cancer Res; 2020 Jul; 9(7):4317-4329. PubMed ID: 35117798
[TBL] [Abstract][Full Text] [Related]
9. Nationwide survey of neuroendocrine carcinoma of the esophagus: a multicenter study conducted among institutions accredited by the Japan Esophageal Society.
Sohda M; Kuwano H; Saeki H; Miyazaki T; Sakai M; Kakeji Y; Toh Y; Doki Y; Matsubara H
J Gastroenterol; 2021 Apr; 56(4):350-359. PubMed ID: 33582864
[TBL] [Abstract][Full Text] [Related]
10. Characterization of tissue chromogranin A (CgA) immunostaining and clinicohistopathological changes for the 125 Chinese patients with primary small cell carcinoma of the esophagus.
Ku JW; Zhang DY; Song X; Li XM; Zhao XK; Lv S; Hu SJ; Cheng R; Zhou FY; Wu HF; Wang LD
Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575250
[TBL] [Abstract][Full Text] [Related]
11. The clinicopathologic features and prognosis of esophageal neuroendocrine carcinomas: a single-center study of 53 resection cases.
Ye L; Lu H; Wu L; Zhang L; Shi H; Wu HM; Tu P; Li M; Wang FY
BMC Cancer; 2019 Dec; 19(1):1234. PubMed ID: 31852479
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
13. [Neuroendocrine carcinoma of cervix: a clinicopathologic study of 82 cases].
Feng M; Zou J; Zhang Y; Sun L
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):328-333. PubMed ID: 29783797
[No Abstract] [Full Text] [Related]
14. [Clinicopathological classification and prognostic factors of gastrointestinal neuroendocrine neoplasms: an analysis of 119 cases].
Ma X; Zhao W; Zhuang C; Wang X; Tu L; Wang M; Sun Y; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):997-1001. PubMed ID: 28900989
[TBL] [Abstract][Full Text] [Related]
15. Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
Zhou HH; Liu LY; Yu GH; Qu GM; Gong PY; Yu X; Yang P
Anticancer Res; 2017 Aug; 37(8):4529-4537. PubMed ID: 28739749
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.
Cattrini C; Cerbone L; Rubagotti A; Zinoli L; Latocca MM; Messina C; Zanardi E; Boccardo F
Clin Genitourin Cancer; 2019 Aug; 17(4):e724-e732. PubMed ID: 31160193
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
Zhu J; Wen H; Bi R; Wu X
J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factor analysis of patients with unresectablelung squamous cell carcinoma].
Gao X; Li Z; Shao XY; Liu XM; Liu C; Liu YP; Qu XJ; Zhang LY
Zhonghua Zhong Liu Za Zhi; 2021 May; 43(5):569-573. PubMed ID: 34034477
[No Abstract] [Full Text] [Related]
19. Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report.
Zhang Y; Liu X; Liang H; Liu W; Wang H; Li T
J Int Med Res; 2023 Jul; 51(7):3000605231187942. PubMed ID: 37498227
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics and prognostic factors of patients with primary gallbladder neuroendocrine carcinomas.
Wang W; Yang CX; Yu XZ; Zhang SL; Wang J; Wang J
J Dig Dis; 2022 Mar; 23(3):166-173. PubMed ID: 35187836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
